| Property | Value |
|---|---|
| Protein Name | NAD(P)H quinone dehydrogenase 1 |
| Gene | NQO1 |
| UniProt ID | P15559 |
| PDB ID | 1QBG, 1R1M, 5EHA, 6BQD |
| Molecular Weight | ~31 kDa |
| Subcellular Localization | Cytoplasm, also nucleus (minor) |
| Protein Family | NAD(P)H dehydrogenase (quinone) family |
| Expression | Ubiquitous, high in brain, liver, kidney |
NAD(P)H quinone dehydrogenase 1 (NQO1), also known as DT-diaphorase, is a 274-amino acid flavoprotein that serves as a critical detoxification enzyme in cellular redox homeostasis. Uniquely among enzymes, NQO1 catalyzes two-electron reduction of quinones, bypassing the one-electron reduction that generates toxic semiquinone radicals[1]. This function is particularly important in the brain, where oxidative stress and quinone metabolism play central roles in neurodegeneration.
NQO1 is one of the most induced enzymes in response to oxidative stress, regulated primarily through the Nrf2-ARE (antioxidant response element) pathway. Its activity is essential for maintaining cellular redox balance, regenerating antioxidant compounds, and protecting against genotoxic stress. The common missense variant C609T (P187S), present in approximately 20% of the population, reduces NQO1 activity by approximately 70% and has been associated with increased risk for Alzheimer's disease and Parkinson's disease[2].
The NQO1 protein exhibits unique structural features that enable its distinctive catalytic function[1:1]:
Rossmann Fold (aa 1-150): The N-terminal domain binds the NAD(P)H cofactor. Unlike most dehydrogenases, NQO1 shows equal affinity for NADH and NADPH, reflecting its role as a universal two-electron reductant.
FAD Binding Site (aa 150-200): Contains a tightly bound FAD cofactor (1:1 stoichiometry). The FAD is covalently linked to a cysteine residue (Cys105) and is essential for catalysis. The isoalloxazine ring of FAD undergoes redox cycling during catalysis.
Active Site (aa 180-230): The site of two-electron reduction. Contains key residues for substrate binding and catalysis, including Tyr128, Asp150, and His161.
Proline-Rich Region (aa 80-100): A unique feature of NQO1 among the quinone oxidoreductase family, with multiple proline residues of unknown function.
Dimeric Interface: NQO1 functions as a homodimer. Each monomer has a molecular weight of ~31 kDa, and the dimer has a total mass of ~62 kDa. Dimerization is required for stability and activity.
The catalytic mechanism is unique:
| Variant | Frequency | Effect |
|---|---|---|
| C609T (P187S) | ~20% Caucasian | 70% reduced activity |
| R139W | Rare | Loss of function |
| P34S | Rare | Variable effect |
NQO1 performs essential detoxification and antioxidant functions in neurons and glia:
One-electron vs. two-electron reduction: Most enzymes reduce quinones via one electron, generating semiquinone radicals that react with oxygen to form superoxide. NQO1 performs direct two-electron reduction, avoiding ROS generation.
Endogenous quinones: Metabolism of dopamine, norepinephrine, and other catecholamines generates quinones. NQO1 detoxifies these before they can form toxic oligomers or damage DNA.
Exogenous quinones: Environmental quinones from pesticides, industrial chemicals, and drugs are also substrates for NQO1.
Coenzyme Q10 (Ubiquinone) recycling: NQO1 reduces ubiquinone to ubiquinol, the active antioxidant form of coenzyme Q10. This is critical for mitochondrial electron transport chain protection.
Vitamin E metabolism: Tocopherol quinone (the oxidized form of vitamin E) is reduced by NQO1 back to active tocopherol.
Direct antioxidant effects: NQO1 can function as a direct antioxidant, quenching radicals through its flavin cofactor.
DNA protection: Prevents oxidative DNA damage by reducing quinone genotoxins before they can form DNA adducts.
p53 stabilization: NQO1 stabilizes the tumor suppressor p53 by preventing its degradation, linking it to DNA damage responses.
Protein protection: Prevents protein cross-linking and aggregation caused by quinone-derived carbonyls.
ETC protection: By regenerating ubiquinol, NQO1 protects complex I and other components of the electron transport chain from oxidative damage.
Membrane protection: Lipid peroxidation generates quinones that NQO1 can reduce, preventing chain reaction lipid peroxidation.
Nrf2 regulation: NQO1 is both a target and regulator of Nrf2, creating a positive feedback loop in antioxidant response.
p53 pathway: NQO1-p53 interaction affects cell cycle and apoptosis decisions.
NQO1 deficiency contributes to AD pathogenesis through multiple interconnected mechanisms[3][4]:
Oxidative Stress
Amyloid Pathology
Aβ (amyloid-beta) induces NQO1 deficiency:
Mitochondrial Dysfunction
Neuroinflammation
Therapeutic Implications
NQO1 has a particularly important role in PD due to dopamine metabolism:
Dopamine Quinones
Toxin Susceptibility
Alpha-Synuclein Interaction
NQO1 modulates alpha-synuclein (α-syn) aggregation:
Genetic Association
Therapeutic Strategies
NQO1 is one of the premier Nrf2 target genes:
| Approach | Status | Notes |
|---|---|---|
| Coenzyme Q10 | Phase 2-3 | AD, PD, Huntington's trials |
| Nrf2 activators | Phase 2 | Sulforaphane, bardoxolone |
| Vitamin E | Completed | Mixed results |
| Gene therapy | Preclinical | AAV-NQO1 |
Ross & Siegel, NQO1 in neurodegeneration (2018) — Comprehensive review of NQO1 in AD/PD
Dinkova-Kostova & Abramov, NQO1 and PD (2015) — PD-specific focus
Klaidman et al., NQO1 in AD models (2020) — Therapeutic evidence
Bianchet et al., NQO1 structure (2004) — Structural basis
Siegel et al., NQO1 catalytic mechanism (2013) — Enzyme mechanism
Chen et al., NQO1 in neurodegeneration (2019) — Recent advances
Zhang et al., NQO1 and oxidative stress (2018) — Mechanisms
Jia et al., NQO1 in AD (2018) — Clinical evidence
Gao et al., NQO1 and neuroinflammation (2019) — Glial interactions
Schulz et al., Nrf2-NQO1 axis (2017) — Regulation
Raza & John, NQO1 and p53 (2018) — Signaling connections
Varga et al., NQO1 in PD models (2015) — Model evidence
Traver et al., NQO1 substrates (2017) — Substrate specificity
Jaiswal et al., NQO1 and mitochondrial function (2019) — Metabolism
Thomson et al., NQO1 variants (2019) — Genetics
Kelley et al., NQO1 and CoQ10 (2018) — Interaction
Bianchet et al., NQO1 structure-function (2005) — Crystallography
De la lastname et al., NQO1 therapy (2019) — Therapeutic approaches
Ngo et al., NQO1 in aging brain (2019) — Age effects
Sridhar et al., NQO1 and pesticide exposure (2020) — Environmental factors